Management of Recurrent Bladder Cancer

Download these slides from a CCO and NCCN on-demand webcast reviewing the latest clinical evidence for the management of recurrent bladder cancer.

For a webcast of this presentation, please visit the NCCN site.

Arlene O. Siefker-Radtke, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.57 MB
Released: August 6, 2021

Acknowledgements

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Astellas and Seattle Genetics, Inc.

Related Content

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 14, 2022 Expired: November 13, 2023

Phase I/II EV-103 cohort K: enfortumab vedotin with or without pembrolizumab as first-line treatment in cisplatin-ineligible locally advanced urothelial cancer, presented at ESMO and reported by Clinical Care Options (CCO)

Released: September 22, 2022

CheckMate 274: pretreatment tumor and immune features and DFS with adjuvant nivolumab in high-risk muscle-invasive UC following radical resection, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

Experts highlight key studies being reported at the upcoming 2022 ESMO Congress in this commentary from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Released: September 8, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings